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Abstract
The utilization of homologous recombination in embryonic stem cells as a means to generate mice
carrying pre-determined modifications of genomic sequences has revolutionized the study of
developmental biology. Recognizing the potential efficiencies that can be obtained by high-throughput
production at centralized technology centers, a number of large-scale efforts for generating mice with
targeted mutations have been funded. These programs are reaching fruition, and a variety of libraries
of embryonic stem cells with defined mutations are now available.
Introduction and context
There can be little doubt that the ability to use
homologous recombination in embryonic stem (ES)
cells as a method to generate mice with defined genomic
modifications has made them the premier model system
for the study of mammalian development and organo-
genesis. This has been further enhanced by recombinase-
based methods that allow mutations to be induced in a
tissue- or temporal-specific fashion. However, the task of
generating mice with genome modifications remains
time- and resource-intensive, and is particularly daunting
for investigators without experience in this domain. This
problem has been recently addressed by the initiation of
large-scale targeted and gene-trap mutagenesis efforts,
many of which have progressed to maturity, providing a
vast resource for investigators wishing to use the mouse
as a model system. The following summarizes the
present status of several of these programs. For addi-
tional information, a thorough review of the history and
methodologies of these and other programs has recently
been published [1].
Major recent advances
In 2004, a proposal was made to pursue a large-scale
project to generate a library of ES cells carrying mutations
of all known or presumptive genes [2]. This effort has
made remarkable progress, and very large numbers of
targeted ES cells are now available to investigators at
modest cost. The project is being undertaken by a
consortium whose diverse responsibilities include the
generation of targeting vectors, the selection and
characterization of mutant ES cells, the distribution of
reagents, and the presentation of data.
The largest components of this effort are represented in
the KOMP (Knock-Out Mouse Project) and EUCOMM
(European Conditional Mouse Mutagenesis) programs.
KOMP was initiated in 2006 and is itself represented in
two complementary efforts [3]. CSD is a collaborative
team from the Children’s Hospital Oakland Research
Institute (CHORI), the Wellcome Trust Sanger Institute,
and the University of California at Davis School of
Veterinary Medicine that has a goal of generating 5000
targeted ES cells. The CSD strategy uses a remarkable
high-throughput method of recombineering developed
at the Sanger Institute to generate targeting vectors that
will generate conditional mutant alleles. This is paired
with an automated ES cell colony-picking technology
and allele characterization by long-range polymerase
chain reaction (PCR). The other major component of
KOMP is an effort by investigators at Regeneron to
generate 3500 deletion alleles. This employs a method of
bacterial artificial chromosome (BAC)-mediated homo-
logous recombination and replacement that they have
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Successful targeting is assayed by using quantitative
PCR to discriminate between wild-type and hemizygous
cell lines for each mutant allele. The KOMP has been
highly productive; as of May 2010 they have generated a
total of 8092 targeting vectors, mutated ES cell lines for
5643 loci, and generated over 300 mutant mouse lines.
EUCOMM is a parallel effort with a goal of generating
8000 targeted conditional mutant alleles [5]. This
program employs the same gene targeting strategy. The
project was developed at the Wellcome Trust Sanger
Institute, the Helmholtz Zentrum München German
Research Center, the Medical Research Council (MRC)
Mammalian Genetics Unit, Harwell, UK, the Institut
Clinique de la Souris, Strasbourg, France, the Consiglio
Nazionale delle Ricerche, Monterotondo, Italy, the
University of Frankfurt, Germany, the Center for
Cardiovascular Research at the Charité, Berlin, Germany,
the University of Technology, Dresden, Germany, and
the European Molecular Biology Laboratory (EMBL),
Monterotondo, Italy. EUCOMM has produced 5980
vectors, 3473 mutated ES cells, and over 400 mutant
mouse lines.
A third major project involving gene targeting by
homologous recombination is being pursued as part of
the NorCOMM (North American Conditional Mouse
Mutagenesis) project [6]. The goal in this effort is up to
500 targeted loci, and the targeting protocol maximizes
the utility of the modified locus for further manipulation
(e.g., replacement with specific mutation [‘knock-in’],
different reporters, recombinases, and so on).
These three projects (and the Texas A&M Institute for
Genomic Medicine, see below) are associated in the
International Knockout Mouse Consortium (IKMC). The
IKMC data coordination center provides unified access to
information about vector design and status of ES cell line
and mutant mouse generation [7]. A genome-view
perspective of alleles that have targeted mutations can
be obtained using the ‘IKMC genes’ ribbon on the
University of California Santa Cruz Genome Browser [8]
or the ‘KO alleles’ DAS (distributed annotation system)
track on the ENSEMBL Genome Browser. A crucial aspect
of any large-scale biological resource is facilitating
distribution; this is done by the KOMP Repository at
the University of California at Davis [9] and by the
European Mouse Mutant Cell Repository (EuMMCR) for
targeted ES cells or from the European Mutant Mouse
Archive (EMMA) for mutant mouse strains. The KOMP
repository also provides blastocyst injection under a
fee-for-service proviso. Note that all vectors can be
obtained for investigators still inclined to ‘do-it-yourself’
gene-targeting.
A unifying aspect of these projects is the use of C57BL/6-
derived ES cells for targeting. This has been an area of
ongoing discussion, in which the efficiency of germ-line
passage obtained using 129-derived lines was balanced
against the desirability of having targeted mutations
isogenic on a C57BL/6 background. The latter was
chosen as a goal for both KOMP and EUCOMM.
Interestingly, this requirement did not specify a sub-
strain, and it has turned out that C57BL/6N has been
more robust for ES cell line development than C57BL/6J.
The feeder-independent JM8 cell line, which is the
primary line used for targeting by the EUCOMM and
KOMP projects, is C57BL/6N-derived [10].
These targeted libraries complement several large gene-
trap resources, such as that generated as part of the
BayGenomics project, the German Gene Trap Consor-
tium, the Toronto Centre for Modelling Human Disease,
and other efforts. Data regarding the insertion sites,
targeting vectors, and transcript characterization for all
publicly available gene-trap cell lines are now curated
and accessible via a central database maintained by the
International Gene-Trap Consortium [11]. A recent
addition is a library originally generated at Lexicon
Genetics and now distributed by the Texas A&M Institute
for Genomic Medicine. This library contains over
350,000 cell lines representing more than 10,000 unique
genes, and is notable for being in C57BL/6N-derived ES
cells [12]. However, the cost of mice generated from this
resource is substantially more than that for mice
obtained from most public-domain programs.
Future directions
While we are potentially on the cusp of a new era in the
utilization of genetically modified mice for develop-
mental analysis, a number of unknowns exist. First and
foremost is the robustness of the newly developed
resource with respect to the generation of germline-
competent mutant mice. Many variables affect this,
including genetic background, genomic stability, culture
conditions, and technical expertise. Both the Sanger
Institute and Regeneron have excellent success in
generating germline-competent mice in their own
facilities. For example, targeted JM8 clones successfully
colonized the germline in over 65% of experiments
[10]. As multiple cell lines have been derived for each
targeted locus, the likelihood of obtaining a germline-
competent mouse for any specific gene of interest is
high. This assumes such success can be obtained
elsewhere.
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created in a C57BL/6N-derived cell line. Although the J
and N substrains are very closely related (only 102 of
139,561 genotyped single-nucleotide polymorphisms
are discordant [10]), several phenotypic differences
have been noted [13,14] and molecular differences,
such as a deletion of the Nnt gene in C57BL/6J, have
been found [15,16].
Finally, there is a spectrum of opinions regarding how
such resources can best be utilized. The European
Community and the Wellcome Trust Sanger Institute
have developed a vigorous effort to support systematized
and centralized phenotyping in a large-scale fashion
[17]. This model has been less consistently embraced by
the research community in the USA. While there are clear
efficiencies and opportunities for discovery inherent by
phenotypic screening in an unbiased fashion, there is
also a case to be made for facilitating analysis by
individual investigators who are invested in specific gene
families, pathways, or phenotypes. As an example,
relatively modest but targeted ENU (N-ethyl-N-nitro-
sourea) mutagenesis programs have been arguably as
productive, with respect to mutation discovery and
functional characterization, as much larger, broadly
focused efforts [18-21].
In summary, an extraordinary resource of gene deletions,
disruptions, and conditional mutant alleles is now
available at relatively low cost to investigators world-
wide. The substantial investment required to create these
libraries is likely to yield substantial insight into the role
of specific genes in mammalian biology.
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